1800-272-662
Shopping Cart 0
countryflagAU
Login

Island Pharmaceuticals Ltd

Healthcare AU ILA

0.45AUD
-0.025(5.26%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.450.48
LowHigh

52 Week Range

0.120.63
LowHigh

Fundamentals

  • Previous Close 0.47
  • Market Cap140.01M
  • Volume222255
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.06M
  • Revenue Per Share TTM-
  • Gross Profit TTM -1.98568M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -3.92014M -2.86432M -2.83045M -2.60689M -2.12676M
Minority interest - - - - -
Net income -3.92014M -2.86432M -2.83045M -2.60689M -2.12676M
Selling general administrative 1.97M 1.44M 1.77M 1.60M 1.90M
Selling and marketing expenses 0.69M 0.35M - - -
Gross profit -1.28592M -1.01099M 0.01M - -
Reconciled depreciation - - - - -
Ebit - -2.86378M -2.89707M -2.80900M -2.13894M
Ebitda - -2.81812M -2.82145M -2.80900M -2.13894M
Depreciation and amortization 3.96M 0.05M - - -
Non operating income net other - - - - -
Operating income -5.35985M -5.13635M -2.89706M -2.80900M -2.13894M
Other operating expenses 5.48M 4.13M - 2.81M 2.14M
Interest expense 0.03M 0.05M 0.00900M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.02M 0.00471M 0.07M 0.20M 0.01M
Net interest income - -0.04149M -0.00900M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.25158M - - -
Total revenue 0.12M 1.25M 0.01M 0.00000M 0.00000M
Total operating expenses 4.07M 4.13M - 2.81M 2.14M
Cost of revenue 1.40M 2.26M - - -
Total other income expense net 1.44M 0.00946M 0.08M 0.20M 0.01M
Discontinued operations - - - - -
Net income from continuing ops - -2.86432M -2.83045M -2.60689M -2.12676M
Net income applicable to common shares -3.92014M -2.86432M -2.83045M -2.60689M -2.12675M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 7.49M 2.56M 2.05M 4.90M 6.64M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.06M 0.01M - - -
Total liab 0.34M 1.05M 0.26M 0.58M 0.24M
Total stockholder equity 7.16M 1.52M 1.79M 4.32M 6.40M
Deferred long term liab - - - - 0.31M
Other current liab 0.19M 0.31M 0.00479M 0.34M 0.15M
Common stock 31.63M 22.39M 19.90M 19.90M 19.83M
Capital stock - - 19.90M 19.90M 19.83M
Retained earnings -25.08488M -21.20006M -19.76326M -4.73430M -2.12741M
Other liab - - - - -
Good will - - - - -
Other assets - - - - 0.31M
Cash 7.25M 1.66M 2.00M 4.79M 6.46M
Cash and equivalents - - - - -
Total current liabilities 0.34M 1.05M 0.26M 0.58M 0.24M
Current deferred revenue - - - - -
Net debt -7.25192M -1.23841M - -4.78744M -6.46064M
Short term debt - 0.42M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - 0.42M - - -
Other stockholder equity - - 1.65M -10.84835M -11.29930M
Property plant equipment - - - - -
Total current assets 7.49M 2.56M 2.05M 4.90M 6.64M
Long term investments - - - - -
Net tangible assets - - 1.79M 4.32M 6.40M
Short term investments - - - - -
Net receivables 0.18M 0.89M 0.02M 0.02M 0.06M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.15M 0.31M 0.11M 0.24M 0.08M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.61M 0.33M - -10.84835M -11.29930M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total - - 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - - - 0.08M
Change to liabilities - - -0.33005M 0.31M 0.23M
Total cashflows from investing activities 0.00000M 0.00000M 0.00000M 0.00000M 0.08M
Net borrowings - 0.20M - - 0.02M
Total cash from financing activities 8.36M 2.79M -0.18036M -0.18036M 7.30M
Change to operating activities - - 0.07M 0.06M -0.10977M
Net income -3.92014M -2.86432M -2.83045M -2.60689M -2.12675M
Change in cash 5.59M -0.33789M -2.78917M -1.67321M 6.46M
Begin period cash flow 1.66M 2.00M 4.79M 6.46M 0.00000M
End period cash flow 7.25M 1.66M 2.00M 4.79M 6.46M
Total cash from operating activities -2.76837M -3.16494M -2.69976M -1.87764M -0.93824M
Issuance of capital stock - 2.73M - - 7.50M
Depreciation - - - - -
Other cashflows from investing activities 0.00000M 0.00000M 0.00000M 0.00000M 0.08M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.71M -0.87344M 0.00366M 0.04M -0.05913M
Sale purchase of stock 9.05M -0.13214M - 0.00000M -0.22193M
Other cashflows from financing activities 0.00630M -0.00976M -0.18036M -0.18036M 0.02M
Change to netincome - - 0.39M 0.32M 1.13M
Capital expenditures 0.00001M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.64M -0.85187M -2.69976M -1.87764M -0.93824M
Stock based compensation 0.34M - - - -
Other non cash items 0.18M 0.55M - - -
Free cash flow -2.76837M -3.16494M -2.69976M -1.87764M -0.93824M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ILA
Island Pharmaceuticals Ltd		 -0.025 5.26% 0.45 - - 2227.72 20.18 990.04 -0.6801
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.

Island Pharmaceuticals Ltd

117 Camberwell Road, Hawthorn East, VIC, Australia, 3123

Key Executives

Name Title Year Born
Dr. Paul Donald Richard MacLeman M.B.A., MBA, BVSc, Grad Dip Tech, Grad Cert Eng, G Exec. Chairman 1966
Dr. David Charles Foster MD, CEO, Pres & Exec. Director NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Paul Donald Richard MacLeman BVSc, D.V.M., F.A.C.I.D., GAICD, Grad Cert Eng, Gr Executive Chairman 1966
Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D. MD, CEO, President & Executive Director NA
Mr. Cameron Jones C.A. Joint Company Secretary NA
Stephanie Vipond Joint Company Secretary NA
Dr. Paul Donald Richard MacLeman BVSc, D.V.M., F.A.C.I.D., GAICD, Grad Cert Eng, Gr Executive Chairman 1966
Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D. MD, CEO, President & Executive Director NA
Mr. Cameron Jones C.A. Joint Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.